DK2857039T3 - Terapeutisk middel eller profylaktisk middel mod demens - Google Patents

Terapeutisk middel eller profylaktisk middel mod demens Download PDF

Info

Publication number
DK2857039T3
DK2857039T3 DK13797290.7T DK13797290T DK2857039T3 DK 2857039 T3 DK2857039 T3 DK 2857039T3 DK 13797290 T DK13797290 T DK 13797290T DK 2857039 T3 DK2857039 T3 DK 2857039T3
Authority
DK
Denmark
Prior art keywords
demens
agent
prophylactic
therapeutic agent
therapeutic
Prior art date
Application number
DK13797290.7T
Other languages
English (en)
Inventor
Hiroshi Mori
Takami Tomiyama
Yoichi Matsumoto
Yuichi Kunori
Hiroshi Eguchi
Original Assignee
Univ Osaka City
Teijin Pharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Osaka City, Teijin Pharma Ltd filed Critical Univ Osaka City
Application granted granted Critical
Publication of DK2857039T3 publication Critical patent/DK2857039T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711Alzheimer's disease; Amyloid plaque core protein
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565Complementarity determining region [CDR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
DK13797290.7T 2012-05-31 2013-05-30 Terapeutisk middel eller profylaktisk middel mod demens DK2857039T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2012124336 2012-05-31
PCT/JP2013/065090 WO2013180238A1 (ja) 2012-05-31 2013-05-30 認知症治療剤又は予防剤

Publications (1)

Publication Number Publication Date
DK2857039T3 true DK2857039T3 (da) 2019-12-16

Family

ID=49673425

Family Applications (1)

Application Number Title Priority Date Filing Date
DK13797290.7T DK2857039T3 (da) 2012-05-31 2013-05-30 Terapeutisk middel eller profylaktisk middel mod demens

Country Status (31)

Country Link
US (3) US20150183854A1 (da)
EP (2) EP3662931B1 (da)
JP (3) JP5971659B2 (da)
KR (2) KR102208283B1 (da)
CN (1) CN104602708B (da)
AR (1) AR091218A1 (da)
AU (2) AU2013268364B2 (da)
BR (1) BR112014029566A2 (da)
CA (1) CA2875205C (da)
CY (1) CY1122530T1 (da)
DK (1) DK2857039T3 (da)
ES (2) ES2973070T3 (da)
HK (1) HK1210031A1 (da)
HR (1) HRP20192267T1 (da)
HU (1) HUE046919T2 (da)
IL (1) IL235899B (da)
LT (1) LT2857039T (da)
ME (1) ME03587B (da)
MX (1) MX361128B (da)
MY (1) MY172458A (da)
NZ (1) NZ630536A (da)
PH (1) PH12014502669A1 (da)
PL (1) PL2857039T3 (da)
PT (1) PT2857039T (da)
RS (1) RS59802B1 (da)
RU (1) RU2657438C2 (da)
SG (2) SG10201805410XA (da)
SI (1) SI2857039T1 (da)
TW (2) TWI700296B (da)
WO (1) WO2013180238A1 (da)
ZA (1) ZA201409186B (da)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2826286C (en) 2011-01-31 2021-09-21 Intellect Neurosciences Inc. Treatment of tauopathies
JP6457263B2 (ja) * 2011-05-20 2019-01-23 オリゴメリックス インコーポレイテッド タウプロテアーゼ組成物および使用方法
SG10201805410XA (en) * 2012-05-31 2018-08-30 Univ Osaka City Therapeutic agent or prophylactic agent for dementia
RU2668159C2 (ru) 2012-07-03 2018-09-26 Вашингтон Юниверсити Антитела против тау
TWI664190B (zh) 2014-06-27 2019-07-01 美商C2N醫療診斷有限責任公司 人類化抗-tau抗體
EP3448875A4 (en) * 2016-04-29 2020-04-08 Voyager Therapeutics, Inc. COMPOSITIONS FOR TREATING A DISEASE
CN109791149A (zh) * 2016-09-30 2019-05-21 豪夫迈·罗氏有限公司 用于功能分析多特异性分子的基于spr的双重结合测定法
WO2018152359A1 (en) 2017-02-17 2018-08-23 Denali Therapeutics Inc. Anti-tau antibodies and methods of use thereof
JP2018139530A (ja) 2017-02-27 2018-09-13 帝人ファーマ株式会社 認知症治療又は予防のためのヒト化抗体及びその製造方法、並びにそれを用いた認知症治療剤又は予防剤
AU2018276554A1 (en) 2017-05-30 2019-10-10 Teijin Pharma Limited Anti-IGF-I receptor antibody
EP3691639B1 (en) 2017-10-02 2023-11-15 Merck Sharp & Dohme LLC Chromane monobactam compounds for the treatment of bacterial infections
JP6851549B2 (ja) 2017-10-16 2021-03-31 エーザイ・アール・アンド・ディー・マネジメント株式会社 抗タウ抗体及びその使用
CN112368300A (zh) 2018-04-06 2021-02-12 帝人制药株式会社 Spns2中和抗体
EP3819378A4 (en) * 2018-07-04 2022-09-14 Aichi Medical University OLIGONUCLEOTIDES FOR CONTROL OF TAU SPLICING AND THEIR USES
CN110028583B (zh) * 2019-05-07 2020-09-11 温州医科大学 抗Tau抗体及其在治疗阿尔茨海默病、创伤性脑损伤中的应用
JP7429404B2 (ja) * 2019-08-06 2024-02-08 慶應義塾 タウ関連疾患モデルの製造方法
US20220365102A1 (en) 2019-09-30 2022-11-17 Nipro Corporation Tau protein detection method using blood sample as test specimen
US20230137434A1 (en) * 2020-03-19 2023-05-04 Vascular Biosciences CAR Peptide for Improved Coronavirus Survival
US20230265175A1 (en) * 2020-06-25 2023-08-24 Merck Sharp & Dohme Llc High affinity antibodies targeting tau phosphorylated at serine 413
WO2023092004A1 (en) 2021-11-17 2023-05-25 Voyager Therapeutics, Inc. Compositions and methods for the treatment of tau-related disorders

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS587390B2 (ja) 1975-03-11 1983-02-09 ツキシマキカイ カブシキガイシヤ ア−クヨウセツホウホウ
JP3587390B2 (ja) 1994-03-17 2004-11-10 タカラバイオ株式会社 リン酸化アミノ酸誘導体及びリン酸化ペプチド合成方法
US20020086009A1 (en) * 1996-03-13 2002-07-04 Koichi Ishiguro Anti-phosphorylated tau protein antibodies and methods for detecting alzheimer`s disease with the use of the same
US20080199471A1 (en) * 2002-03-01 2008-08-21 Bernett Matthew J Optimized cd40 antibodies and methods of using the same
US8012936B2 (en) 2006-03-29 2011-09-06 New York University Tau fragments for immunotherapy
US20070280935A1 (en) * 2006-04-07 2007-12-06 Bernd Bohrmann Antibody that recognizes phosphorylated peptides
US20080076145A1 (en) * 2006-06-16 2008-03-27 En Vivo Pharmaceuticals, Inc. Transgenic flies expressing tau and amyloid precursor fragment
UA107571C2 (xx) * 2009-04-03 2015-01-26 Фармацевтична композиція
CN106390107B (zh) * 2009-06-10 2019-12-31 纽约大学 病理tau蛋白的免疫靶向
US8609097B2 (en) 2009-06-10 2013-12-17 Hoffmann-La Roche Inc. Use of an anti-Tau pS422 antibody for the treatment of brain diseases
CA2826286C (en) * 2011-01-31 2021-09-21 Intellect Neurosciences Inc. Treatment of tauopathies
TR201102696U (tr) * 2011-05-27 2011-06-21 Turhal Sal�H Bağlantısız hareketli ürün reklam standı.
SG10201805410XA (en) * 2012-05-31 2018-08-30 Univ Osaka City Therapeutic agent or prophylactic agent for dementia

Also Published As

Publication number Publication date
HUE046919T2 (hu) 2020-04-28
RU2014153099A (ru) 2016-07-20
EP3662931A1 (en) 2020-06-10
TWI700296B (zh) 2020-08-01
CA2875205A1 (en) 2013-12-05
KR102208283B1 (ko) 2021-01-26
LT2857039T (lt) 2020-03-10
MX361128B (es) 2018-11-28
TWI777183B (zh) 2022-09-11
MX2014014187A (es) 2015-06-04
RS59802B1 (sr) 2020-02-28
ZA201409186B (en) 2015-12-23
JPWO2013180238A1 (ja) 2016-01-21
JP6620829B2 (ja) 2019-12-18
CN104602708B (zh) 2021-11-30
PT2857039T (pt) 2020-01-07
TW201410705A (zh) 2014-03-16
CN104602708A (zh) 2015-05-06
AR091218A1 (es) 2015-01-21
EP2857039B1 (en) 2019-11-20
HRP20192267T1 (hr) 2020-03-20
PH12014502669B1 (en) 2015-02-02
PH12014502669A1 (en) 2015-02-02
AU2013268364B2 (en) 2018-02-08
CY1122530T1 (el) 2021-01-27
JP6406678B2 (ja) 2018-10-17
MY172458A (en) 2019-11-26
ES2763361T3 (es) 2020-05-28
SG10201805410XA (en) 2018-08-30
US20220340646A1 (en) 2022-10-27
AU2013268364A1 (en) 2014-12-18
IL235899B (en) 2019-03-31
SI2857039T1 (sl) 2020-03-31
SG11201407878VA (en) 2015-01-29
AU2018200413A1 (en) 2018-02-08
RU2657438C2 (ru) 2018-06-13
HK1210031A1 (en) 2016-04-15
JP5971659B2 (ja) 2016-08-17
ES2973070T3 (es) 2024-06-18
CA2875205C (en) 2021-07-20
AU2018200413B2 (en) 2019-10-17
WO2013180238A1 (ja) 2013-12-05
PL2857039T3 (pl) 2020-05-18
ME03587B (me) 2020-07-20
KR102133610B1 (ko) 2020-07-14
JP2018111716A (ja) 2018-07-19
EP2857039A4 (en) 2015-08-26
US20200148753A1 (en) 2020-05-14
EP3662931B1 (en) 2023-12-06
TW202041532A (zh) 2020-11-16
BR112014029566A2 (pt) 2017-07-25
JP2016147902A (ja) 2016-08-18
KR20150027098A (ko) 2015-03-11
IL235899A0 (en) 2015-01-29
NZ630536A (en) 2017-03-31
US20150183854A1 (en) 2015-07-02
KR20200029619A (ko) 2020-03-18
EP2857039A1 (en) 2015-04-08

Similar Documents

Publication Publication Date Title
DK2857039T3 (da) Terapeutisk middel eller profylaktisk middel mod demens
DK2891492T3 (da) Endoparasit kontrol middel
BR302012006715S1 (pt) Configuração aplicada em lâmina
BR302012004879S1 (pt) Configuração aplicada em esfigmomanômetro
DK2760886T3 (da) Immunocytokin-kombinationsterapi
DK3033242T3 (da) Cykloidalt hjuldrev
FI20115876A0 (fi) Yhdistelmähoito
DK2861573T3 (da) Oxathiazin-derivater som antibakterielle og anticancer-stoffer
BR112015014842A2 (pt) agente de indução de apoptose
BR302012003683S1 (pt) Configuração aplicada em poltrona
DK2914574T3 (da) Ny fremgangsmåde
DK2628798T3 (da) Profylaktisk eller terapeutisk middel mod fibrose
FI20115640A0 (fi) Yhdistelmähoito
DE112013005825A5 (de) Reduktionsmittelzuführeinrichtung
DK2735290T3 (da) Protese eller ortose
DK2900234T3 (da) Kræft-kemoterapeutisk middel/formulering, fremstilling og anvendelse deraf
DE112013001653A5 (de) Carben-Übertragungsreagenz
DK2735291T3 (da) Protese eller ortose
PL395785A1 (pl) Zastosowanie medyczne N-etylo-3-amino-4-fenylo-5-okso-2,5-dihydro-1H-pirazolo-1-karbotioamidu
DK2456445T3 (da) Middel til behandling af hudlidelser
BR302012002260S1 (pt) Configuração aplicada em hélice
AT12073U2 (de) Rettungs- und notatemgerät
BR302012005541S1 (pt) Configuração aplicada em caderno
UA25744S (uk) Крісло
BR302012004413S1 (pt) Configuração aplicada em poltrona